SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-033054
Filing Date
2023-03-16
Accepted
2023-03-16 07:22:43
Documents
13
Period of Report
2023-03-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tm239317-2_8k.htm   iXBRL 8-K 29991
2 EXHIBIT 99.1 tm239317d2_ex99-1.htm EX-99.1 68121
  Complete submission text file 0001104659-23-033054.txt   286507

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acxp-20230316.xsd EX-101.SCH 3042
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acxp-20230316_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acxp-20230316_pre.xml EX-101.PRE 22601
7 EXTRACTED XBRL INSTANCE DOCUMENT tm239317-2_8k_htm.xml XML 3607
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40536 | Film No.: 23737119
SIC: 2834 Pharmaceutical Preparations